Zacks Investment Research lowered shares of Zafgen, Inc. (NASDAQ:ZFGN) from a buy rating to a hold rating in a research report report published on Friday.

According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, ValuEngine lowered shares of Zafgen from a sell rating to a strong sell rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $6.38.

Zafgen (ZFGN) traded down 2.03% during trading on Friday, reaching $3.37. 158,390 shares of the company traded hands. The firm’s 50 day moving average price is $3.45 and its 200 day moving average price is $3.98. Zafgen has a 12-month low of $2.89 and a 12-month high of $5.46. The firm’s market capitalization is $92.62 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the prior year, the business posted ($0.55) earnings per share. Equities research analysts expect that Zafgen will post ($2.23) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Zafgen, Inc. (ZFGN) Lowered to Hold at Zacks Investment Research” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/09/16/zafgen-inc-zfgn-lowered-to-hold-at-zacks-investment-research.html.

In related news, insider Dennis D. Kim bought 10,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The stock was purchased at an average cost of $3.39 per share, with a total value of $33,900.00. Following the transaction, the insider now owns 21,443 shares in the company, valued at approximately $72,691.77. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 21.20% of the company’s stock.

Large investors have recently bought and sold shares of the company. Algert Global LLC purchased a new stake in shares of Zafgen in the 2nd quarter worth about $123,000. Parametric Portfolio Associates LLC lifted its position in shares of Zafgen by 55.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 10,327 shares during the period. Wells Fargo & Company MN lifted its position in shares of Zafgen by 1,290.3% in the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 40,400 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Zafgen in the 2nd quarter worth about $259,000. Finally, LMR Partners LLP purchased a new stake in shares of Zafgen in the 2nd quarter worth about $299,000. 48.52% of the stock is owned by hedge funds and other institutional investors.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.